NightHawk Biosciences（纽约证券交易所代码：NHWK）股价跌破200日移动平均线1.31美元

NightHawk Biosciences, Inc. (NYSE:NHWK – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.31 and traded as low as $0.87. NightHawk Biosciences shares last traded at $0.87, with a volume of 44,063 shares.

NightHawk Biosciences Trading Down 3.1 %

The firm has a market capitalization of $22.32 million, a PE ratio of -0.49 and a beta of 0.57. The business has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $1.31. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.08.

Institutional Trading of NightHawk Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Edmond DE Rothschild Holding S.A. acquired a new position in NightHawk Biosciences during the 3rd quarter worth about $25,000. Bank of New York Mellon Corp purchased a new position in shares of NightHawk Biosciences in the third quarter valued at approximately $25,000. Renaissance Technologies LLC purchased a new position in shares of NightHawk Biosciences in the third quarter valued at approximately $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of NightHawk Biosciences in the third quarter worth $57,000. Finally, Virtu Financial LLC acquired a new position in shares of NightHawk Biosciences in the fourth quarter worth $53,000. Hedge funds and other institutional investors own 9.52% of the company's stock.

About NightHawk Biosciences

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Read More

• Get a free copy of the StockNews.com research report on NightHawk Biosciences (NHWK)
• On Holding AG Sprints Higher on Margin Expansion and Guidance
• Price Growth & Yield: For That Magical Combo, Leave the U.S.
• Game-Changing News For Tesla Investors
• DOW New Hghs Coming Sooner Than Later
• The Tide Is Turning For Harley-Davidson

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.